Drugs / muparfostat
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00073892 | Jan 2004 → Nov 2005 | cancer of unknown primary site, cutaneous melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 1/2 | NCT00068172 | Jul 2001 → Jun 2007 | melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT00268593 | Aug 2005 → Feb 2008 | prostate cancer | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00130442 | Jun 2005 → Oct 2010 | melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00247728 | Jun 2004 → Jun 2008 | hepatocellular carcinoma | Cellxpert Biotechnology Corp. | Completed | Missed primary |
| Phase 2 | NCT00103389 | Feb 2004 → May 2007 | lung cancer | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00097851 | Feb 2004 → Jul 2006 | non-small cell lung carcinoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01402908 | Aug 2011 → Jul 2014 | hepatocellular carcinoma | Cellxpert Biotechnology Corp. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00568308 | Dec 2007 → Jul 2008 | hepatocellular carcinoma | Progen Pharmaceuticals | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Medigen Vaccine Biologics Corp. | Results 成大沈延盛教授團隊與基亞合作發表- PI-88具調控胰臟癌微環境並提升化療療效之潛力 com.tw ↗
研究結果顯示，PI-88 在不具細胞毒性的條件下抑制 HPSE，可阻斷纖維化相關訊號來減緩結締組織增生與調整腫瘤微環境，達到增強化療的效果。 |
| 2007-07-09 | Medigen Vaccine Biologics Corp. | Regulatory 兩群台灣人的賭注 換來抗癌大突破 com.tw ↗
這意味著 FDA 肯定臨床實驗的結果，並裁定該藥品可以不需要完成第二期的第二階段，直接進入第三期的人體實驗，讓藥品加快上市腳步。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Medigen Vaccine Biologics Corp. | 成大沈延盛教授團隊與基亞合作發表- PI-88具調控胰臟癌微環境並提升化療療效之潛力 com.tw ↗ |
| 2007-07-09 | Medigen Vaccine Biologics Corp. | 兩群台灣人的賭注 換來抗癌大突破 com.tw ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | muparfostat | “PI-88 (muparfostat) 190 mg daily by subcutaneous injection” NCT00130442 ↗ |
| Known as | MUPARFOSTAT SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297163 ↗ |
| Known as | PI-88 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00068172 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor A inhibitor” CHEMBL4297163 ↗4“Acidic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ “Basic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ “heparanase inhibitor PI-88” PMID 25170226 ↗ Aug 2014 “Heparanase inhibitor” CHEMBL4297163 ↗ |
| Modality | Other / unclassified | “a novel heparanase inhibitor” PMID 19303160 ↗ Feb 2009 |
| Route | Subcutaneous | “The drug will be injected subcutaneously (under the skin) once daily for 4 days every week.” NCT00068172 ↗ |
| Target | FGF1 | “Acidic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ |
| Target | FGF2 | “Basic fibroblast growth factor inhibitor” CHEMBL4297163 ↗ |
| Target | HPSE | “Heparanase inhibitor” CHEMBL4297163 ↗ |
| Target | VEGFA | “Vascular endothelial growth factor A inhibitor” CHEMBL4297163 ↗ |